Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MOUNTAIN VIEW, Calif., May 6, 2013 /PRNewswire/ -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that the Company has been selected to present its AZ-002 (Staccato® alprazolam) program at the Pipeline Session of the Antiepileptic Drug and Device Trials (AED) XII Conference, the premier conference devoted to convening the full spectrum of research, industry and regulatory expertise in the epilepsy field with the objective of accelerating the most promising epilepsy therapies in development. The three-day AED XII conference will feature clinical and scientific thought leaders addressing antiepileptic drug and medical technology development from preclinical- through late-stage clinical programs. The conference will take place on May 15-17, 2013 at the Turnberry Isle Miami Hotel, Aventura, Florida. James V. Cassella, PhD, Alexza Executive Vice President, Research and Development and Chief Scientific Officer will be speaking at 1:45 p.m. Eastern Time on Friday, May 17, 2013.
According to the Epilepsy Foundation, with nearly three million affected in the U.S. alone, epilepsy is as common as breast cancer and almost as prevalent as Alzheimer’s disease.
“We are excited that Alexza’s AZ-002 product candidate will be highlighted in the Pipeline Session at the AED XII Conference before such a high caliber group of scientific, clinical and industry representatives,” said James V. Cassella, PhD. “Staccato alprazolam is being developed for the treatment of acute repetitive seizures (ARS). ARS occurs in a small subset of patients with epilepsy who regularly experience breakthrough seizures in flurries or clusters, despite treatment with a regimen of anti-epileptic drugs.”
“Now in its twelfth year, the Antiepileptic Drug and Device Trials XII Conference spans the range of topics in epilepsy research and development as one of the leading scientific forums in the field. Offering the most current thinking on the treatment, diagnosis, global regulatory environment and therapies in development, AED XII provides a forum for the acceleration of new treatments and treatment practices that we hope will ultimately benefit people with epilepsy and seizure disorders,” said Jacqueline French, MD, Director of the Epilepsy Study Consortium, Director of Clinical Trials at NYU‘s Comprehensive Epilepsy Center and current President of the American Epilepsy Society.
AED XII is sponsored by the Epilepsy Study Consortium in collaboration with the University of Pennsylvania Epilepsy Center and the Epilepsy Therapy Project, an initiative of the Epilepsy Foundation. For additional information on the AED XII program and speakers or to register, please visit http://www.epilepsy.com/etp/aedtrialxii.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions, including agitation, acute repetitive seizures and insomnia. Alexza’s products are based on the Staccato® system, a hand-held inhaler that is designed to deliver a drug aerosol to the deep lung, providing rapid systemic delivery and therapeutic onset with ease and convenience for patients.
ADASUVE® (Staccato loxapine) is Alexza’s first product, which was approved by the U.S. Food and Drug Administration in December 2012 and by the European Medicines Agency in February 2013. Grupo Ferrer Internacional, S.A. is Alexza’s commercial partner for ADASUVE in Europe, Latin America, Russia and the Commonwealth of Independent States countries.
For more information about Alexza, the Staccato system technology or the Company’s development programs, please visit www.alexza.com. For more information about ADASUVE, please visit www.adasuve.com.
ADASUVE® and Staccato® are registered trademarks of Alexza Pharmaceuticals, Inc.
Safe Harbor Statement
This news release and the upcoming presentation will contain forward-looking statements that involve significant risks and uncertainties. Any statement describing the Company’s expectations or beliefs is a forward-looking statement, as defined in the Private Securities Litigation Reform Act of 1995, and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of developing and commercializing drugs, including the adequacy of the Company’s capital to support the Company’s operations, and the Company’s ability to raise additional funds and the potential terms of such potential financings, the ability for Alexza and Ferrer to effectively and profitably commercialize ADASUVE and the timing of the projected commercialization of ADASUVE. The Company’s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning Alexza’s business are described in additional detail in the Company’s Annual Report on Form 10-K for the year ended December 31, 2012 and the Company’s other Periodic and Current Reports filed with the Securities and Exchange Commission. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
SOURCE Alexza Pharmaceuticals, Inc.
Help employers find you! Check out all the jobs and post your resume.
